| Literature DB >> 30010676 |
Arjang Hassibi1, Arun Manickam1, Rituraj Singh1, Sara Bolouki1, Ruma Sinha1, Kshama B Jirage1, Mark W McDermott1, Babak Hassibi2, Haris Vikalo3, Gelareh Mazarei1, Lei Pei1, Luc Bousse1, Mark Miller1, Mehrdad Heshami1, Michael P Savage1, Michael T Taylor1, Nader Gamini1, Nicholas Wood1, Pallavi Mantina1, Patrick Grogan1, Peter Kuimelis1, Piyush Savalia1, Scott Conradson1, Yuan Li1, Rich B Meyer1, Edmond Ku1, Jessica Ebert1, Benjamin A Pinsky4, Gregory Dolganov1, Tran Van1, Kirsten A Johnson1, Pejman Naraghi-Arani1, Robert G Kuimelis1, Gary Schoolnik1,4.
Abstract
The emergence of pathogens resistant to existing antimicrobial drugs is a growing worldwide health crisis that threatens a return to the pre-antibiotic era. To decrease the overuse of antibiotics, molecular diagnostics systems are needed that can rapidly identify pathogens in a clinical sample and determine the presence of mutations that confer drug resistance at the point of care. We developed a fully integrated, miniaturized semiconductor biochip and closed-tube detection chemistry that performs multiplex nucleic acid amplification and sequence analysis. The approach had a high dynamic range of quantification of microbial load and was able to perform comprehensive mutation analysis on up to 1,000 sequences or strands simultaneously in <2 h. We detected and quantified multiple DNA and RNA respiratory viruses in clinical samples with complete concordance to a commercially available test. We also identified 54 drug-resistance-associated mutations that were present in six genes of Mycobacterium tuberculosis, all of which were confirmed by next-generation sequencing.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30010676 DOI: 10.1038/nbt.4179
Source DB: PubMed Journal: Nat Biotechnol ISSN: 1087-0156 Impact factor: 54.908